Glaucoma

Robert Stamper, MD, gives key takeaways from his G360 presentation, "Home tonometry: Worth the pressure?"

SpyGlass Pharma presented new data at the Glaucoma 360 New Horizons Forum that supports the use of their proprietary drug delivery platform to lower IOP in patients with glaucoma or ocular hypertension.

A look back on what's happened in optometry during the week of Jan. 28-Feb. 2.

Researchers found that the use of atropine drops after glaucoma surgery may impact vision and prolong rehabilitation time.

A look back on what's happened in optometry during the week of Jan. 21-Jan. 26.

A look back on what's happened in optometry during the week of Jan. 14-Jan. 19.

Novel drops for a variety of indications are under investigation.

A look back on what's happened in optometry during the week of Jan. 1-Jan. 5, 2023.

As Baby Boomers enter the at-risk age group for vision loss, optometrists must be ready to act.

The 'Screen, Protect, Cure' campaign aims to education individuals who may be at risk for glaucoma, while raising funding for glaucoma research during Glaucoma Awareness Month.

One individual’s habit can be the demise of good health.

As 2022 comes to a close, check out some of the hottest and most-liked stories from the year!

A meditation on the effects of putting off doctors' orders.

Austin Lifferth, OD, FAAO, shares highlights from his AAOpt 2022 presentations, including a triad approach to evaluating the optic nerve in glaucoma, and recentering glaucoma care with these 5 GlaucoMantras.

Researchers reported that the preclinical detectable phase for OAG is about 10 years.

Justin Schweitzer, OD, gives a brief overview of his EyeCon 2022 presentations, reflecting on pipeline advancements made in optometry in 2022.

The glaucoma field is on the move with significant innovations in a number of treatment areas. Experts discussed the various technologies at the Optometry Times 2022 EyeCon meeting in Marco Island, Florida.

As the first and only preservative-free formulation of latanoprost, IYUZEH 0.005% is approved to reduce IOP in patients with open-angle glaucoma or ocular hypertension.

Glaucoma therapy isn't as cookie-cutter as it seems on the surface.

It was reported that the more individuals smoke, the faster the retinal nerve fiber layer (RNFL) becomes thinner.

Optometrists must identify and mitigate complications for this patient base.

Several risk factors beyond intraocular pressure contribute to open-angle glaucoma.

A recent report shows that 61 drugs were associated with the development of acute angle-closure (AAC) glaucoma.

Potential for treatment strategy to prevent blindness from glaucoma.

Recent patient situation stresses needs for peer-to-peer discourse.